1 山東羅欣藥業集團股份有限公司
1,803,663,000 10.77% 199,206,000 11.08% 二零一六年中期報告 2
3 871,206 851,933 1,803,663 1,628,297 (225,855) (340,123) (505,037) (548,781) 645,351 511,810 1,298,626 1,079,516 3 10,002 18,772 20,956 34,021 17,500 2,327 36,365 4,727 (503,534) (351,163) (949,993) (747,611) (62,424) (50,648) (156,708) (112,447) 5 106,895 131,098 249,246 258,206 6 (24,312) (15,359) (48,690) (34,181) 82,583 115,739 200,556 224,025 17 11 82,600 115,739 200,567 224,025 3 山東羅欣藥業集團股份有限公司
81,631 115,809 199,206 224,018 952 (70) 1,350 7 82,583 115,739 200,556 224,025 81,648 115,809 199,217 224,018 952 (70) 1,350 7 82,600 115,739 200,567 224,025 7 13.39 18.99 32.68 36.75 二零一六年中期報告 4
79,921 70,287 8 4,057 4,057 5,080 8,021 9 801,143 754,293 119,849 108,136 10 99,526 99,675 1,218 1,218 165 165 1,110,959 1,045,852 306,922 241,986 11 588,535 524,848 215,110 172,602 12 1,048,195 1,049,556 503,669 605,333 2,662,431 2,594,325 13 244,810 130,188 433,712 643,027 54,944 56,423 213,360 53,765 48,600 1,000,591 878,238 5 山東羅欣藥業集團股份有限公司
1,661,840 1,716,087 2,772,799 2,761,939 110,179 89,526 2,662,620 2,672,413 14 60,960 60,960 78,151 78,128 213,360 2,499,911 2,300,705 2,639,022 2,653,153 23,598 19,260 2,662,620 2,672,413 二零一六年中期報告 6
60,960 31,139 41,272 6,033 (316) 2,514,065 2,653,153 19,260 2,672,413 11 199,206 199,217 1,350 200,567 4,900 4,900 12 12 (1,912) (1,900) (213,360) (213,360) (213,360) 60,960 31,139 41,272 6,033 (304) 11 2,499,911 2,639,022 23,598 2,662,620 60,960 31,139 36,390 6,033 2,208,898 2,343,420 3,796 2,347,216 224,018 224,018 7 224,025 164 164 18,306 18,470 (182,880) (182,880) (182,880) 60,960 31,139 36,390 6,033 164 2,250,036 2,384,722 22,109 2,406,831 7 山東羅欣藥業集團股份有限公司
1,434 420,113 (108,009) (89,933) 4,900 26,324 (101,675) 356,504 11 605,333 160,512 503,669 517,016 503,669 517,016 二零一六年中期報告 8
1. 46,000,000 H 9 山東羅欣藥業集團股份有限公司
2. 34 2 17 2 36 二零一六年中期報告 10
3. 1,803,663 1,628,297 19,635 32,958 1,321 1,063 20,956 34,021 1,824,619 1,662,318 11 山東羅欣藥業集團股份有限公司
4. 587 516 36,345 32,041 2,441 133 965 564 145,453 147,216 95,809 56,503 2,975 2,019 5. 48,690 34,181 6. 二零一六年中期報告 12
7. 199,206,000 609,600,000 224,018,000 609,600,000 8. 17,450 17,450 4,057 4,057 4,057 17,450 21,507 4,057 17,450 21,507 17,450 17,450 17,450 17,450 17,450 17,450 4,057 4,057 4,057 4,057 13 山東羅欣藥業集團股份有限公司
9. 735,883 734 73,499 (43,122) 221,858 988,852 16,909 68,727 (7,455) 1,067,033 191,608 60,261 (17,310) 234,559 36,345 (5,014) 265,890 801,143 754,293 17,162,000 16,753,000 19,183,000 12,395,000 二零一六年中期報告 14
10. 50 70 52,597 50,927 (1,918) 101,606 816 (965) 101,457 1,931 1,931 99,526 99,675 101,457 101,606 8,843 8,914 92,614 92,692 101,457 101,606 15 山東羅欣藥業集團股份有限公司
11. 1 90 481,802 443,720 91 180 60,186 63,087 181 365 41,500 18,041 365 6,638 1,591 590,126 526,439 (1,591) (1,591) 588,535 524,848 180 12. 1,048,195,000 1,049,556,000 8 8 二零一六年中期報告 16
13. 1 90 177,193 88,021 91 180 11,172 6,587 181 365 9,936 6,738 365 46,509 28,842 244,810 130,188 14. H 0.10 609,600 44,504 16,456 60,960 0.10 609,600 44,504 16,456 60,960 15. 115,000 140,134 74,765 74,215 17 山東羅欣藥業集團股份有限公司
16. (i) 138,070 218,281 (ii) 27,061 25,947 (iii) 24,559 15,712 : (i) (ii) 51% (iii) 51% 二零一六年中期報告 18
17. (i) (ii) (iii) 1,048,195 1,048,195 991,481 991,481 19 山東羅欣藥業集團股份有限公司
17. 1,048,195 991,481 18. 1,900,000 3.8% 1,900,000 1,900,000 12,000 19. 二零一六年中期報告 20
0.35 21 山東羅欣藥業集團股份有限公司
OTC (1) (2) (3) 二零一六年中期報告 22
1. 23 山東羅欣藥業集團股份有限公司
CJ 12420 CJ HealthCare CJ 12420 CJ 12420 CJ 12420 III P-CAB CJ 12420 H+ K+ ATPase CJ 12420 CJ 12420 SCC 31 SCC 31 二零一六年中期報告 24
(ATP) mtor mtorc1 mtorc2 PI3K-AKT-mTOR 50% mtor mtor mtor mtorc1 25 山東羅欣藥業集團股份有限公司
2. 3 307 6 (1) 0.25g 0.75g (2) 0.5g 3. (1) 93 142 (2) 307 (3) 48 (4) 13 6 10 4 二零一六年中期報告 26
1. (1) 1601 GMP GMP 27 山東羅欣藥業集團股份有限公司
(2) GMP 42 GMP 1 GMP (3) GMP EUGMP GMP 2. OTC 二零一六年中期報告 28
(%) 809,022 692,930 44.85% 42.55% 16.75% 560,737 589,430 31.09% 36.20% 4.87% 433,904 345,937 24.06% 21.25% 25.43% 1,803,663 1,628,297 100% 100% 10.77% 3 2014S00718 3.2 3.1 29 山東羅欣藥業集團股份有限公司
1,803,663,000 1,628,297,000 10.77% 505,037,000 548,781,000 7.97% 72.00% 66.30% 5.70% 1,106,701,000 860,058,000 28.68% 1. 2. 199,206,000 224,018,000 11.08% 32.68 503,669,000 517,016,000 二零一六年中期報告 30
4,571,000 1,041,000,000 1,045,000,000 300,000,000 3.40% 60,000,000 3.00% 90,000,000 3.20% 116,000,000 3.15% 115,000,000 3.20% 210,000,000 3.10% 100,000,000 3.10% 50,000,000 2.60% 31 山東羅欣藥業集團股份有限公司
二零一六年中期報告 32
GMP 2025 33 山東羅欣藥業集團股份有限公司
二零一六年中期報告 34
XV 352 5.46 1. 325,639,949 73.17% 53.42% 2. 25,865,000 51.73% 7,450,000 14.90% 5,000,000 10.00% 1,000,000 2.00% 10,685,000 21.37% 35 山東羅欣藥業集團股份有限公司
325,639,949 325,639,949 51.73% 325,639,949 XV 352 5.46 XV 336 1. 325,639,949 73.17% 53.42% 二零一六年中期報告 36
2. H H H GL Capital Management GP Limited 1 26,166,000 15.90% 4.29% Lion River I N.V 2 3 4 26,802,000 16.29% 4.39% GL Partners Capital Management Limited 2 26,166,000 15.90% 4.29% 5 26,802,000 16.29% 4.39% Li Zhenfu 6 26,166,000 15.90% 4.29% 1 GL Trade Investment Limited GL Trade Investment 26,166,000 H GL Trade Investment GL Capital Management GP Limited GL Capital Management GL Capital Management 26,166,000 H 2 GL Capital Management GL Partners Capital Management Limited GL Partners Lion River I N.V. 51% 49% GL Partners Lion River I N.V. GL Trade Investment 26,166,000 H 37 山東羅欣藥業集團股份有限公司
3 GL Healthcare Investment L.P. 518,758 H GL Healthcare Investment L.P. GL China Opportunities Fund II (Canada) L.P. 84.77% GL China Opportunities Fund II (Canada) L.P. Lion River I. N.V. 84.77% Lion River I. N.V. GL Healthcare Investment L.P. 518,758 H 4 GL China Long Equity Opportunities Fund SPV LP 117,242 H GL China Long Equity Opportunities Fund SPV LP GL China Long Equity Opportunities Fund LP GL China Long Equity Opportunities Fund LP Lion River I. N.V. Lion River I. N.V. GL China Long Equity Opportunities Fund SPV LP 117,242 H 5 Lion River IN.V. 26,802,000 H 6 Li Zhenfu GL Partners 70% 26,166,000 H XV 336 二零一六年中期報告 38
5.48 5.67 11.04 81.56% 39 山東羅欣藥業集團股份有限公司
10 (www.hkgem.com) http://shandongluoxin.quamir.com 二零一六年中期報告 40